Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Conditions › Glioblastoma multiforme

Glioblastoma multiforme

Part of Glioma

2 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for Glioblastoma multiforme

60 trials tracked for Glioblastoma multiforme: 1 in phase 3 or 4.

60Trials tracked
1Phase 3 & 4
0Recruiting
0With published results
Phase distribution
Phase 3 1 Phase 2 52 Phase 1 4 Other / NA 3
  1. Phase 3 Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed
  2. Phase 2 Enzastaurin Before and Concomitant With Radiation, Followed by Enzastaurin in Participants With Newly Diagnosed Glioblastoma Completed
  3. Phase 2 Oral Pazopanib Plus Oral Topotecan Metronomic Antiangiogenic Therapy for Recurrent Glioblastoma Multiforme (A) Without Prior Bevacizumab Exposure and (B) After Failing Prior Bevacizumab Completed
  4. Phase 2 A Study of Bevacizumab and Extended Treatment of Temozolomide in Patients With Recurrent Glioblastoma Multiforme Completed
  5. Phase 2 Temozolomide Chronotherapy for High Grade Glioma Completed
  6. Phase 2 Hypofractionated Intensity-Modulated Radiation Therapy With Temozolomide and Bevacizumab for Glioblastoma Multiforme Completed
Show 44 more trials
  1. Phase 2 FET-PET for Evaluation of Response of Recurrent GBM to Avastin Completed
  2. Phase 2 Convection-Enhanced Delivery (CED) of MDNA55 in Adults With Recurrent or Progressive Glioblastoma Completed
  3. Phase 2 A Study of Avastin (Bevacizumab) and Irinotecan Versus Temozolomide Radiochemistry in Patients With Glioblastoma Completed
  4. Phase 2 Bevacizumab and Temozolomide Following Radiation and Chemotherapy for Newly Diagnosed Glioblastoma Multiforme Completed
  5. Phase 2 Phase 1-2 of Temozolomide and Hypofractionated Radiotherapy in Tx of Supratentorial Glioblastoma Multiform Completed
  6. Phase 2 Phase 1/2 Study of Enzastaurin in Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma (GS) Patients Completed
  7. Phase 2 A Study of ICT-107 Immunotherapy in Glioblastoma Multiforme (GBM) Completed
  8. Phase 2 Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib for Glioblastoma Multiforme Completed
  9. Phase 2 Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme Completed
  10. Phase 2 PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation Completed
  11. Phase 2 Cilengitide (EMD 121974) for Recurrent Glioblastoma Multiforme (Brain Tumor) Completed
  12. Phase 2 Thalidomide and Temozolomide or Camptothecin-11 (CPT-11) in Patients With Gliomas Completed
  13. Phase 2 Bevacizumab in Combination With Metronomic Temozolomide for Recurrent Malignant Glioma Completed
  14. Phase 2 A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma Completed
  15. Phase 2 Efficacy, Safety and CNS Exposure of G-202 (Mipsagargin) in Patients With Recurrent or Progressive Glioblastoma Completed
  16. Phase 2 Study to Assess Safety, Pharmacokinetics, and Efficacy of Oral CC-223 for Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma or Multiple Myeloma Completed
  17. Phase 2 Repeated Super-Selective Intraarterial Cerebral Infusion of Bevacizumab (Avastin) for Treatment of Newly Diagnosed GBM Completed
  18. Phase 2 Oral Tarceva Study for Recurrent/Residual Glioblastoma Multiforme and Anaplastic Astrocytoma Completed
  19. Phase 2 Combination of BKM120 and Bevacizumab in Refractory Solid Tumors and Relapsed/Refractory Glioblastoma Multiforme Completed
  20. Phase 2 Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer Completed
  21. Phase 2 Avastin/Temozolomide/Irinotecan for Unresectable/Multifocal Glioblastoma Multiforme Completed
  22. Phase 2 Zactima With Temodar During Radiation Treatment for Newly Diagnosed Stage IV Brain Tumors Completed
  23. Phase 2 Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors Completed
  24. Phase 2 A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma Completed
  25. Phase 2 A Randomized Phase II Trial of Vandetanib (ZD6474) in Combination With Carboplatin Versus Carboplatin Alone Followed by Vandetanib Alone in Adults With Recurrent High-Grade Gliomas Completed
  26. Phase 2 Amgen 386 for Recurrent Glioblastoma Completed
  27. Phase 2 DC Migration Study for Newly-Diagnosed GBM Completed
  28. Phase 2 Study of XL184 (Cabozantinib) in Adults With Glioblastoma Multiforme Completed
  29. Phase 2 A Study of MEDI-575 in Subjects With Recurrent Glioblastoma Multiforme Completed
  30. Phase 2 BrUOG 263: Prostate Specific Membrane Antigen (PSMA) Glioblastoma Multiforme (GBM) Completed
  31. Phase 2 Phase I/II Evaluation of Temozolomide and ZARNESTRA (R115777) for Recurrent and Progressive Glioblastoma Multiforme Completed
  32. Phase 2 RT, Temozolomide, and Bevacizumab Followed by Bevacizumab/Everolimus in First-line Treatment of GBM Completed
  33. Phase 2 Valproic Acid, Radiation, and Bevacizumab in Children With High Grade Gliomas or Diffuse Intrinsic Pontine Glioma Completed
  34. Phase 2 6-TG, Capecitabine and Celecoxib Plus TMZ or CCNU for Anaplastic Glioma Patients Completed
  35. Phase 2 Safety and Efficacy Study of Tarceva, Temodar, and Radiation Therapy in Patients With Newly Diagnosed Brain Tumors Completed
  36. Phase 2 Vaccine Therapy for the Treatment of Newly Diagnosed Glioblastoma Multiforme Completed
  37. Phase 2 Temozolomide Alone or in Combination With Thalidomide and/or Isotretinoin and/or Celecoxib in Treating Patients Who Have Undergone Radiation Therapy for Glioblastoma Multiforme Completed
  38. Phase 2 Protein Phosphatase 2A Inhibitor, in Recurrent Glioblastoma Completed
  39. Phase 2 Phase II Feasibility Study of Dendritic Cell Vaccination for Newly Diagnosed Glioblastoma Multiforme Completed
  40. Phase 2 Phase I/II Study To Test The Safety and Efficacy of TVI-Brain-1 As A Treatment For Recurrent Grade IV Glioma Completed
  41. Phase 2 Border Zone Stereotactic Radiosurgery With Bevacizumab in Patients With Glioblastoma Multiforme Completed
  42. Phase 2 Phase 2a Study of CAN-2409 With Standard Radiation Therapy for Malignant Glioma Completed
  43. Phase 2 Study To Test the Safety and Efficacy of TVI-Brain-1 As A Treatment for Recurrent Grade IV Glioma Completed
  44. Phase 2 Disulfiram/Copper With Concurrent Radiation Therapy and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed

Showing the 50 most-cited and recently-updated of 60 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Glioblastoma multiforme: what the trials found

In a phase 3 trial, imatinib mesylate showed limited efficacy in glioblastoma multiforme, with progression-free survival rates of 5.3%, 6.6%, 2.1%, and 2.1% during the study duration 1.

A phase 2 trial of temozolomide reported grade 3 or 4 lymphopenia (2 patients), thrombocytopenia (0), neutropenia (1), leukopenia (0), and anemia (0 in one group; 1 in another) 2. Quality of life changes were also assessed, with physical well-being scores ranging from 4.00 to 8.32 and social/family well-being scores from 22.45 to 24.29 2.

Recent results — preliminary, needs further review

  • A phase 2 trial of pp65-shLAMP DC with GM-CSF reported no significant improvement in overall survival (16.9 vs 16.2 vs 20.6 months, p=0.196) or progression-free survival (6.1 vs 6.4 vs 7.1 months, p=0.354), but a significant difference in ELISPOT assay (126.3 vs 48.4 vs -162.7, p=0.038) 4.
  • A phase 2 trial of valproic acid showed improved 1-year event-free survival (12 vs 24 events, p<0.05) but grade 3 thrombocytopenia (1%) and neutropenia (3%) were noted 18.
  • A phase 2 trial of unpulsed DCs reported median overall survival of 16, 20, and 19 months (p=0.072) and a significant difference in dendritic cell migration to lymph nodes (6.0% vs 9%, p=0.0195) 16.
  • A phase 2 trial of SL-701 with poly-ICLC reported overall survival at 12 months (20 vs 14 patients) and progression-free survival at 6 and 12 months (1.9 vs 5.6 months) 10.
  • A phase 2 trial of topotecan reported progression-free survival at 6 months for bevacizumab-naive patients (0.44) and at 3 months for prior bevacizumab patients (0.18, 0.11, 0) 21.

For the clinician treating this condition

  • Imatinib mesylate demonstrated limited efficacy in glioblastoma, with low progression-free survival rates 1.
  • Temozolomide was associated with manageable hematologic toxicities and variable quality of life outcomes 2.
  • Several phase 2 trials have explored novel agents, but none have yet shown definitive survival benefits in established settings.

AI synthesis of 7 cited trials, updated Jun 27, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes
Oncology Meta-analysis
Meta-analysis of bevacizumab therapy in recurrent glioblastoma multiforme shows associations with improved outcomes Bevacizumab therapy linked to better survival and fewer bleeding risks in recurrent brain cancer
This meta-analysis evaluates bevacizumab (BEV) therapy, temozolomide (TMZ), and lomustine in patients with recurrent glioblastoma multiforme…
A large review of patients with recurrent brain cancer found bevacizumab therapy linked to better survival and fewer bleeding risks compared…
May 1, 2026
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme
Oncology Cohort
PINK1 expression quantified by IHC in adults with newly diagnosed IDH-wild type glioblastoma multiforme A Simple Brain Tumor Test Could Predict Your Treatment Path
This prospective observational cohort study evaluated PINK1 expression in adults (18+ years) with newly diagnosed IDH-wild type glioblastoma…
A specific protein in glioblastoma tissue could forecast survival odds, helping patients plan care even though the test is not available yet…
medRxiv Apr 10, 2026

Research across Glioma

Related studies from across the Glioma family.

5-ALA fluorescence-guided surgery improves gross total resection rates in patients with glioblastoma
Oncology Meta-analysis
5-ALA fluorescence-guided surgery improves gross total resection rates in patients with glioblastoma Fluorescence guided surgery improves tumor removal for glioblastoma patients
This meta-analysis of 790 patients found that 5-ALA guided surgery significantly improved gross total resection (RR = 1.54, 95% CI: 1.16-2.0…
A special light guide helps surgeons remove more of a brain tumor while keeping patient safety and recovery rates steady.
Jul 26, 2026
Prodigiosin shows theoretical potential as a radiosensitiser for glioblastoma based on multifaceted cytotoxic activity
Drug Pipeline Sys. Review
Prodigiosin shows theoretical potential as a radiosensitiser for glioblastoma based on multifaceted cytotoxic activity Prodigiosin Shows Potential as a Treatment for Glioblastoma
This narrative review explores the biological profile of prodigiosin (PG) in the context of glioblastoma. The authors suggest PG may act as …
A new review suggests that the compound prodigiosin could help make radiation more effective against glioblastoma brain tumors.
Frontiers Jul 25, 2026
Metabolic reprogramming of myeloid cells shapes spatial niches and immunometabolic landscapes in brain tumors
Oncology Meta-analysis
Metabolic reprogramming of myeloid cells shapes spatial niches and immunometabolic landscapes in brain tumors New research explores how cell metabolism shapes brain tumor growth
This systematic review synthesizes the role of myeloid cell metabolism within the immunometabolic landscape of brain tumors. It explores how…
Scientists are mapping out how the energy use of specific immune cells helps shape the environment inside glioblastoma tumors.
Frontiers Jul 16, 2026
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management
Oncology Meta-analysis
Synergistic Effects of Immune Checkpoint Inhibitors and Radiotherapy in Solid Tumor Management Combining immune checkpoint inhibitors and radiotherapy improves survival outcomes
Meta-analysis data indicates that combining immune checkpoint inhibitors with radiotherapy significantly improves survival outcomes in solid…
New data shows that adding immune checkpoint inhibitors to radiation therapy can improve survival for patients with many types of solid tumo…
Jul 9, 2026
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy
Allergy & Immunology Sys. Review
Meningeal Immune System Offers New Target for Glioblastoma Immunotherapy New approach targets the immune system to treat brain tumors
This systematic review explores how targeting the meningeal immune system, including dural lymphatics and rBAMs, could overcome current barr…
A new strategy focuses on the area where brain tumors meet the body's defenses to improve how immunotherapy works for glioblastoma.
Frontiers Jun 15, 2026
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma
Allergy & Immunology Sys. Review
Dysregulation of the TOX/TCF-1 axis and IDH-mutation driven silencing drive cytotoxic failure in glioblastoma Single-cell atlas reveals how glioblastoma disables immune cells
This systematic review examines the immunological landscape of glioblastoma, specifically focusing on cytotoxic lymphocyte dysfunction. The …
A systematic review maps the cellular and molecular mechanisms behind immune failure in glioblastoma, identifying key targets for future the…
Frontiers Jun 10, 2026
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients
Oncology Meta-analysis
Meta-analysis links high platelet ratios to worse overall survival in adult glioblastoma patients High blood cell ratios linked to shorter life in glioblastoma patients
This meta-analysis reviews data from 2609 patients with WHO grade 4 diffuse astrocytoma to evaluate platelet indices. High platelet: lymphoc…
High blood cell ratios are linked to shorter life in glioblastoma patients. This analysis of over 5,000 adults shows how simple blood tests …
May 23, 2026
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib
Pulmonology & Critical Care Sys. Review
Case report suggests second primary glioblastoma in ALK-positive lung adenocarcinoma patient treated with ensartinib and lorlatinib A single patient case warns doctors to check for second cancers when tumors act strangely
This case report describes a 63-year-old female with ALK-positive lung adenocarcinoma who received ensartinib, lorlatinib, and stereotactic …
A 63-year-old woman with lung cancer developed a new brain tumor that was not a metastasis. Doctors must carefully examine unusual tumor gro…
Frontiers May 16, 2026
Review of glioma organoid models for mechanistic discovery and therapy development
Oncology Sys. Review
Review of glioma organoid models for mechanistic discovery and therapy development Finally Lab-Grown Brain Models Could Speed Up Glioma Treatments
This narrative review summarizes glioma organoid model systems for studying tumor-neural interactions. It concludes these models provide a f…
• Tiny lab-grown brains mimic real tumor behavior better than old methods • Kids and adults fighting deadly brain cancers like glioblastoma …
Frontiers May 15, 2026
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis
Rheumatology Meta-analysis
Tumor treating fields plus chemotherapy improved survival outcomes for newly diagnosed and recurrent glioblastoma patients in this meta-analysis Brain Cancer Survival Jumps When Adding This Therapy to Chemo
A systematic review and meta-analysis of 2,376 patients found that adding tumor treating fields to chemotherapy significantly prolonged prog…
Adding a wearable electric field device to standard chemotherapy helps glioblastoma patients live significantly longer with similar major si…
Frontiers May 8, 2026
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer
Oncology Sys. Review
Narrative review covers hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pancreatic cancer, and non-small cell lung cancer A Hidden Protein Switch May Fuel Cancer Growth and Drug Resistance
This narrative review addresses multiple malignancies including hepatocellular carcinoma, colorectal cancer, glioblastoma, breast cancer, pa…
A single protein called PRMT3 helps multiple cancers grow, hide from the immune system, and resist chemotherapy, making it a promising new t…
Frontiers May 5, 2026
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma
Genetics & Precision Medicine Meta-analysis
Meta-analysis of preclinical models shows enhanced outcomes for focused ultrasound gene therapy in glioblastoma Ultrasound Opens a New Door for Brain Cancer Treatment
This systematic review and meta-analysis evaluated focused ultrasound mediated gene therapy in preclinical orthotopic glioblastoma in vivo m…
A new review of nine studies shows that focused ultrasound can safely deliver gene therapy across the brain's protective barrier, shrinking …
May 4, 2026